In summary, by using an unbiased screening we identified here several pathways and compounds with the ability to downregulate TRF1 levels in both lung cancer and glioblastoma cells, including inhibitors of the Ras pathway (ERK and MEK), the cell cycle‐related CDK inhibitor, the inhibitor of the chaperone HSP90, RTK, and mTOR inhibitors (Fig 1D), and two chemotherapeutic agents (gemcitabine and docetaxel). This evidence concerns the gene MAP2K7 and lung carcinoma.